Navigation Links
Study links arm/hand swelling to number of lymph nodes removed during breast cancer surgery
Date:4/23/2009

In older breast cancer survivors, the number of lymph nodes removed during surgery and the presence of cancer in the lymph nodes were the two factors most directly linked to the development of lymphedema, swelling of the arm and hand, according to a study from the Medical College of Wisconsin's Center for Patient Care and Outcomes Research in Milwaukee, Wisconsin.

"Lymphedema causes physical discomfort and disability, as well as a cosmetic deformity which can lead to anxiety, depression and emotional distress that can affect a woman's activities of daily living and quality of life," says lead author Tina Yen, M.D., M.S., a Medical College of Wisconsin surgical oncologist who practices at Froedtert Hospital, a major hospital affiliate. "For these reasons, lymphedema is probably the most feared complication among breast cancer survivors. A better understanding of its risk factors is needed to help improve outcomes."

The study appears online, in advance of publication in the April issue of Annals of Surgical Oncology. It is significant because there are few large, population-based studies on this topic looking at long-term outcomes from more than one institution, and much of the existing literature was written 20-30 years ago, when more extensive surgeries to the breast and armpit (axilla) were performed and use of radiation therapy to the armpit was more common.

The researchers conducted three phone surveys between 2005 and 2007 among 1,338 community-dwelling women, ages 65-89 years, who were identified by Medicare claims as having undergone initial breast cancer surgery in 2003. These 1,338 women were treated by 707 surgeons. Four years after surgery, 14 percent self-reported having lymphedema.

Women who developed lymphedema were more likely to have more extensive disease, have undergone more extensive surgery and received chemotherapy. However, after controlling for a woman's age, tumor size, type of surgery, other therapies and surgeon volume, the removal of more than five lymph nodes and the presence of cancer in the lymph nodes were the only two factors that predicted a risk for lymphedema. Most importantly, the number of lymph nodes removed is more predictive of the risk for lymphedema rather than the type of axillary surgery performed (sentinel lymph node biopsy versus axillary node dissection).

If no lymph nodes were removed, the risk for lymphedema was 4.7 percent. Removal of up to five lymph nodes did not increase the risk of lymphedema, when compared to the removal of no lymph nodes. However, the removal of between six and 15 lymph nodes increased that risk five-fold, and removal of 16 or more lymph nodes increased the risk of developing lymphedema by more than ten-fold. Given these findings, all women undergoing any axillary surgery should still be counseled on their risk for lymphedema, although this risk may be minimal for women who have fewer than five lymph nodes removed.


'/>"/>

Contact: Toranj Marphetia
toranj@mcw.edu
414-955-4700
Medical College of Wisconsin
Source:Eurekalert

Related medicine news :

1. New study argues for CT colonography as primary colon cancer screening test
2. Patients Had Fewer Infection Rates, Fewer Complications at Blue Distinction Centers for Bariatric Surgery(R), According to HealthCore Study
3. Pennsaid(R) Phase 3 study results to be published in leading international PAIN journal
4. Facet Solutions Completes 1 Year Follow-up on U.S. Pilot Study
5. BUSM study finds photographs of UV exposure can impact sunburns in preteens
6. Telesso initiates post-market head-to-head peripheral IV catheter study
7. FDA Grants Ethicon Endo-Surgery Approval of Its IDE Application to Commence Study of Notes Toolbox(TM)
8. New Study Shows Fish Oil Improves Cholesterol Levels in Professional Football Players
9. Transave Completes Enrollment in Arikace(TM) Phase II Bronchiectasis Study
10. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
11. Mexicos health insurance success offers lessons for US reforms, Lancet study suggests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... ... Usually, the impending arrival of warmer weather means the gleeful banishment of ... chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic Laser ... chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the fat ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... release of two biometric time and attendance tracking products: the new NCheck Cloud ... NCheck Cloud Bio Attendance uses biometric face recognition to enable users to check ...
(Date:3/28/2017)... ... ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio and New ... sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National Advisory Board., ... the clinic from a small start-up to number 78 in the country based on ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Lice ... Atlantic City March 13-16, was a busy spot this year. Liz Solovay and ... strategies for preventing outbreaks among camp communities during the upcoming 2017 camping season. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Nurse practitioners ... as their value increases in the healthcare workforce, according to a survey recently ... boards, career fairs, and candidate leads to healthcare employers of physicians and advanced ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Israel , March 28, 2017 Emosis ... This new business entity, Emosis Ltd, headquartered in Tel ... of novel assays complementing the mother company existing technology platform and ... and sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. ...
(Date:3/28/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a ... commercialization of innovative therapies for the treatment of ... Agency (EMA) has notified the company that the ... Application (MAA) has passed validation, and that the ... MAA for ARX-04 (known as DSUVIA™ in the ...
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
Breaking Medicine Technology: